. 2020 Jul 8;10:11201. doi: 10.1038/s41598-020-68209-6

Table 3.

Comparison of our study with literature.

	Authors	Population	SRT schedule	Median follow-up	Med survival	Local control	Cerebral control	Toxicities	Salvage therapy
100% NSCLC	Bowden 2015¹² Retrospective	N = 720 nBM = 1 (38%)-19 RPA ≤ 2: 98% Previous WBRT 52%	18-20 Gy/1f ID 50–80% GK	8 months (range 1–124)	8.5 months (95% CI 0.5–158)	80%	58%	NR	24%
Zairi 2014¹¹ Retrospective	N = 89 nBM = 1 (82%)-6 RPA ≤ 2: 78%	18–26 Gy/1f ID 50% GK	28 months (range 1–99)	24 months (95% CI NR)	At 1 year: 91.5%	At 1 year: 79%	Acute: 10% G1-2 0% G3-4	22%
Our study Retrospective	N = 100 nBM = 1 (67%)-6 DS-GPA ≥ 2.5: 48.5% RPA ≤ 2: 88%	18-36 Gy/1-5f ID 80% CK	33 months (range 20–64)	10.1 months (95% CI 7.8–13.9)	At 1 year: 78.7%	At 1 year: 43%	Acute : 15% G1-2 2% G3	30%

Authors

Population

SRT schedule

Median follow-up

Med survival

Local control

Cerebral control

Toxicities

Salvage therapy

100% NSCLC

Bowden 2015¹²

Retrospective

N = 720

nBM = 1 (38%)-19

RPA ≤ 2: 98%

Previous WBRT 52%

18-20 Gy/1f

ID 50–80%

8 months (range 1–124)

8.5 months (95% CI 0.5–158)

80%

58%

24%

Zairi 2014¹¹

Retrospective

N = 89

nBM = 1 (82%)-6

RPA ≤ 2: 78%

18–26 Gy/1f

ID 50%

28 months (range 1–99)

24 months (95% CI NR)

At 1 year: 91.5%

At 1 year: 79%

Acute:

10% G1-2

0% G3-4

22%

Our study

Retrospective

N = 100

nBM = 1 (67%)-6

DS-GPA ≥ 2.5: 48.5%

RPA ≤ 2: 88%

18-36 Gy/1-5f

ID 80%

33 months (range 20–64)

10.1 months (95% CI 7.8–13.9)

At 1 year: 78.7%

At 1 year: 43%

Acute :

15% G1-2

2% G3

30%

LC lung cancer, UK unknown, nBM number of BM treated by patient, ID Isodose, GK Gammaknife™, CK Cyberknife™, LINAC linear accelerator.